Department of Anesthesiology, University of Utah, School of Medicine, Salt Lake City, UT 84312, USA.
Biomaterials. 2011 Jan;32(1):288-94. doi: 10.1016/j.biomaterials.2010.08.092. Epub 2010 Oct 6.
Pulmonary edema and the associated increases in vascular permeability continue to represent a significant clinical problem in the intensive care setting, with no current treatment modality other than supportive care and mechanical ventilation. Therapeutic compound(s) capable of attenuating changes in vascular barrier function would represent a significant advance in critical care medicine. We have previously reported the development of HPMA-based copolymers, targeted to endothelial glycocalyx that are able to enhance barrier function. In this work, we report the refinement of copolymer design and extend our physiological studies to demonstrate that the polymers: 1) reduce both shear stress and pressure-mediated increase in hydraulic conductivity, 2) reduce nitric oxide production in response to elevated hydrostatic pressure and, 3) reduce the capillary filtration coefficient (K(fc)) in an isolated perfused mouse lung model. These copolymers represent an important tool for use in mechanotransduction research and a novel strategy for developing clinically useful copolymers for the treatment of vascular permeability.
肺水肿和相关的血管通透性增加在重症监护环境中仍然是一个重大的临床问题,除了支持性护理和机械通气外,目前没有其他治疗方法。能够减轻血管屏障功能变化的治疗化合物将是重症医学的重大进展。我们之前曾报道过靶向内皮糖萼的基于 HPMA 的共聚物的开发,这些共聚物能够增强屏障功能。在这项工作中,我们改进了共聚物的设计,并扩展了我们的生理研究,以证明这些聚合物:1)降低剪切应力和压力介导的水力传导率增加,2)降低一氧化氮的产生以响应升高的静水压力,和 3)降低在分离灌注的小鼠肺模型中的毛细血管滤过系数(K(fc))。这些共聚物代表了用于机械转导研究的重要工具,也是开发用于治疗血管通透性的临床有用共聚物的新策略。